Michiel Rienstra

Background

About Michiel Rienstra

Clinical SummaryGraduated in medicine at the University of Antwerp, Belgium in 2003. Cardiologist since 2012, with focus on management of arrhythmias (atrial fibrillation) and heart failure. Clinical Director of the Department of Cardiology, University Medical Center Groningen, responsible for patient quality and safety. Chair of the Heart Center consisting of Department of Cardiology and Cardiothoracic Surgery. Initiator of HartNet, a regional network organisation of first, second and third line heartcare for inhabitants of the provinces of Groningen en Drenthe, supported by patient organisations and health care insurances. Involved in numerous institutional committes (Value-based Health Care program, Certification, Clinical capacity, member Stafconvent board, chair CdCs, etc.).Research SummaryObtained a PhD at the University of Groningen, The Netherlands in 2007 on Atrial Fibrillation, Underlying Disease and Prognosis. I completed my cardiology training at the University Medical Center Groningen in 2012, where continued working as clinical cardiologist and researcher. I was awarded with a NWO Rubicon grant in 2009 and went to Harvard Medical School, Massachusetts General Hospital and the Framingham Heart Study for a post-doc on population genetics and epidemiology in 2010-2011. In 2012 I was awarded with the NWO Veni grant for his project on genetics of atrial fibrillation. In 2015 I was awarded with the European Society of Cardiology academic grant for his project on a big data approach in atrial fibrillation. I am also part of several CVON consortia, and in steering cie of multiple investigator-initiatied trials on AF and/or HF. I am fellow of the European Society of Cardiology and the American Heart Association, and Leadership committee member of the Functional Genomics and Translational Biology council.My clinical-oriented research consists of conducting clinical studies to improve AF treatment (RACE I to V, CONVERT, VIP-HF), studying epidemiology of AF and its risk factors in PREVEND, Lifelines and Framingham Heart Study, uncovering the genetics of atrial fibrillation in part with the CHARGE-AF/AFGen international consortium, and applying novel bioinformatics tools to improve AF risk prediction.